Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 10,092 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 10,092 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96. Following the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at approximately $35,701,010.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Todd Harris also recently made the following trade(s):

• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total value of $14,406.00.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total value of $138,518.38.

Tyra Biosciences Stock Down 0.3 %

Shares of TYRA stock opened at $23.34 on Friday. The stock has a market cap of $1.23 billion, a P/E ratio of -13.89 and a beta of 1.01. The company’s fifty day simple moving average is $21.62 and its two-hundred day simple moving average is $18.86. Tyra Biosciences, Inc. has a 52 week low of $10.38 and a 52 week high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Analysts Set New Price Targets

TYRA has been the subject of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Oppenheimer raised their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Finally, Piper Sandler assumed coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Tyra Biosciences has an average rating of “Moderate Buy” and a consensus target price of $26.40.

Hedge Funds Weigh In On Tyra Biosciences

Several institutional investors have recently bought and sold shares of the business. HighVista Strategies LLC bought a new position in shares of Tyra Biosciences in the 2nd quarter valued at about $257,000. Rhumbline Advisers increased its stake in Tyra Biosciences by 12.3% during the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after acquiring an additional 2,574 shares during the last quarter. Bank of New York Mellon Corp raised its position in Tyra Biosciences by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after purchasing an additional 14,352 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of Tyra Biosciences in the 1st quarter valued at approximately $977,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after purchasing an additional 8,324 shares during the period. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.